Oestrogen: An overlooked mediator in the neuropsychopharmacology of treatment response?

International Journal of Neuropsychopharmacology

Volumn 14, Issue 4, 2011, Pages 553-566

  Keating, Charlotte ^a   Tilbrook, Alan ^b   Kulkarni, Jayashri ^a  

^a The Alfred ^*  (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Anorexia nervosa; antidepressant; estrogen; HPA axis; major depression

Indexed keywords

3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; 5 HYDROXYINDOLEACETIC ACID; ANTIDEPRESSANT AGENT; CITALOPRAM; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CORTICOTROPIN; CP 316 311; ESCITALOPRAM; ESTRADIOL; ESTROGEN; FLUOXETINE; HORMONE ANTAGONIST; HYDROCORTISONE; MOOD STABILIZER; NITROMIFENE; PLACEBO; PROGESTERONE; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ANOREXIA NERVOSA; CENTRAL NERVOUS SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; HORMONE SUBSTITUTION; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; LOW DRUG DOSE; MAJOR DEPRESSION; MENOPAUSE; MOOD DISORDER; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REMISSION; REVIEW; SEROTONINERGIC SYSTEM; STRESS; TREATMENT RESPONSE;

ADRENOCORTICOTROPIC HORMONE; ANOREXIA NERVOSA; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; ESTROGENS; FEMALE; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY-ADRENAL SYSTEM; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 79960373319     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145710000982     Document Type: Review

References (119)

1. Abraham S, Luscombe G, Soo I (2003). Oral contraception and cyclic changes in premenstrual and menstrual experiences. Journal of Psychosomatic Obstetrics & Gynaecology 24, 185-193. (Pubitemid 37338826)
2. Abraham SF, Pettigrew B, Boyd C, Russell J, et al. (2005). Usefulness of amenorrhoea in the diagnoses of eating disorder patients. Journal of Psychosomatic Obstetrics & Gynaecology 26, 211-215. (Pubitemid 41367524)
3. Abumaria N, Rygula R, Hiemke C, Fuchs E, et al. (2007). Effect of chronic citalopram on serotonin-related and stress-regulated genes in the dorsal raphe nucleus of the rat. European Journal of Neuropsychopharmacology 17, 417-429. (Pubitemid 46497654)
4. Angold A, Costello EJ, Worthman CM (1998). Puberty and depression: the roles of age, pubertal status and pubertal timing. Psychological Medicine 28, 51-61. (Pubitemid 28043568)
5. Attia E, Haiman C, Walsh BT, Flater SR (1998). Does fluoxetine augment the inpatient treatment of anorexia nervosa? American Journal of Psychiatry 155, 548-551. (Pubitemid 28207453)
6. Bailer UF, Frank GK, Henry SE, Price JC, et al. (2005). Altered brain serotonin 5-HT1A receptor binding after recovery from anorexia nervosa measured by positron emission tomography and [carbonyl11C]WAY-100635. Archives of General Psychiatry 62, 1032-1041. (Pubitemid 41248383)
7. Bailer UF, Frank GK, Henry SE, Price JC, et al. (2007). Serotonin transporter binding after recovery from eating disorders. Psychopharmacology (Berlin) 195, 315-324.
8. Barbarich-Marsteller NC (2007). Neurochemistry and pharmacological treatments : Where is the field of anorexia nervosa heading? Central Nervous System Agents in Medicinal Chemistry 7, 35-43. (Pubitemid 46440370)
9. Barton DA, Esler MD, Dawood T, Lambert EA, et al. (2008). Elevated brain serotonin turnover in patients with depression: effect of genotype and therapy. Archives of General Psychiatry 65, 38-46.
10. Behl C, Manthey D (2000). Neuroprotective activities of estrogen : an update. Journal of Neurocytology 29, 351-358.
11. Bergh C, Sodersten P (1996). Anorexia nervosa, selfstarvation and the reward of stress. Nature Medicine 2, 21-22. (Pubitemid 26029568)
12. Bethea CL, Lu NZ, Gundlah C, Streicher JM (2002). Diverse actions of ovarian steroids in the serotonin neural system. Frontiers in Neuroendocrinology 23, 41-100. (Pubitemid 34121908)
13. Bethea CL, Mirkes SJ, Shively CA, Adams MR (2000). Steroid regulation of tryptophan hydroxylase protein in the dorsal raphe of macaques. Biological Psychiatry 47, 562-576. (Pubitemid 30129085)
14. Bethea CL, Reddy AP, Tokuyama Y, Henderson JA, et al. (2009). Protective actions of ovarian hormones in the serotonin system of macaques. Frontiers in Neuroendocrinology 30, 212-238.
15. Bhagwagar Z, Hinz R, Taylor M, Fancy S, et al. (2006). Increased 5-HT(2A). receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [(11)C]MDL 100,907. American Journal of Psychiatry 163, 1580-1587. (Pubitemid 44465759)
16. Bhagwagar Z, Murthy N, Selvaraj S, Hinz R, et al. (2007). 5-HTT binding in recovered depressed patients and healthy volunteers : a positron emission tomography study with [11C]DASB. American Journal of Psychiatry 164, 1858-1865. (Pubitemid 351739239)
17. Biederman J, Herzog DB, Rivinus TM, Harper GP, et al. (1985). Amitriptyline in the treatment of anorexia nervosa: a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology 5, 10-16. (Pubitemid 15126295)
18. Binder EB, Kunzel HE, Nickel T, Kern N, et al. (2009). HPA axis regulation at in-patient admission is associated with antidepressant therapy outcome in male but not in female depressed patients. Psychoneuroendocrinology 34, 99-109.
19. Binneman B, Feltner D, Kolluri S, Shi Y, et al. (2008). A 6-week randomized, placebo-controlled trial of CP- 316,311 (a selective CRH1 antagonist) in the treatment of major depression. American Journal of Psychiatry 165, 617-620. (Pubitemid 351705339)
20. Blier P, de Montigny C (1999). Serotonin and drug-induced therapeutic responses in major depression, obsessivecompulsive and panic disorders. Neuropsychopharmacology 21 (Suppl. 2), 91S-98S. (Pubitemid 29396476)
21. Brambilla F, Ferrari E, Brunetta M, Peirone A, et al. (1996). Immunoendocrine aspects of anorexia nervosa. Psychiatry Research 62, 97-104. (Pubitemid 26151793)
22. Burt VK, Quezada V (2009). Mood disorders in women: focus on reproductive psychiatry in the 21st century - Motherisk update 2008. Canadian Journal of Clinical Pharmacology 16, e6-e14.
23. Chrousos GP, Torpy DJ, Gold PW (1998). Interactions between the hypothalamic-pituitary-adrenal axis and the female reproductive system: clinical implications. Annals of Internal Medicine 129, 229-240. (Pubitemid 28377514)
24. Cohen LS, Soares CN, Vitonis AF, Otto MW, et al. (2006). Risk for new onset of depression during the menopausal transition : the Harvard study of moods and cycles. Archives of General Psychiatry 63, 385-390.
25. Crow SJ, Mitchell JE, Roerig JD, Steffen K (2009). What potential role is there for medication treatment in anorexia nervosa? International Journal of Eating Disorders 42, 1-8.
26. Cyr M, Calon F, Morissette M, Di Paolo T (2002). Estrogenic modulation of brain activity : implications for schizophrenia and Parkinsons disease. Journal of Psychiatry and Neuroscience 27, 12-27. (Pubitemid 34478366)
27. Dalle Grave R, Calugi S, Marchesini G (2008). Is amenorrhea a clinically useful criterion for the diagnosis of anorexia nervosa? Behaviour Research and Therapy 46, 1290-1294.
28. Davis C (1997). Eating disorders and hyperactivity : a psychobiological perspective. Canadian Journal of Psychiatry 42, 168-175. (Pubitemid 27181947)
29. Davis C, Woodside DB (2002). Sensitivity to the rewarding effects of food and exercise in the eating disorders. Comprehensive Psychiatry 43, 189-194. (Pubitemid 34507466)
30. Del Rio G, Velardo A, Zizzo G, Avogaro A, et al. (1994). Effect of estradiol on the sympathoadrenal response to mental stress in normal men. Journal of Clinical Endocrinology & Metabolism 79, 836-840. (Pubitemid 24286412)
31. Doris A, Ebmeier K, Shajahan P (1999). Depressive illness. Lancet 354, 1369-1375. (Pubitemid 29481640)
32. Fava M, Kendler KS (2000). Major depressive disorder. Neuron 28, 335-341.
33. Freeman EW, Sammel MD, Lin H, Nelson DB (2006). Associations of hormones and menopausal status with depressed mood in women with no history of depression. Archives of General Psychiatry 63, 375-382.
34. Garfinkel PE, Lin E, Goering P, Spegg C, et al. (1996). Should amenorrhoea be necessary for the diagnosis of anorexia nervosa? Evidence from a Canadian community sample. British Journal of Psychiatry 168, 500-506.
35. Gjerris A, Sorensen AS, Rafaelsen OJ, Werdelin L, et al. (1987). 5-HT and 5-HIAA in cerebrospinal fluid in depression. Journal of Affective Disorders 12, 13-22. (Pubitemid 17047120)
36. Gleason CE, Carlsson CM, Johnson S, Atwood C, et al. (2006). Clinical pharmacology and differential cognitive efficacy of estrogen preparations. Annals of the New York Academy of Sciences 1052, 93-115.
37. Gold PW, Chrousos GP (2002). Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs. low CRH/NE states. Molecular Psychiatry 7, 254-275. (Pubitemid 34280634)
38. Gorwood P (2004). Eating disorders, serotonin transporter polymorphisms and potential treatment response. American Journal of Pharmacogenomics 4, 9-17. (Pubitemid 38325701)
39. Gotlib IH, Whiffen VE, Mount JH, Milne K, et al. (1989). Prevalence rates and demographic characteristics associated with depression in pregnancy and the postpartum. Journal of Consulting and Clinical Psychology 57, 269-274. (Pubitemid 20079806)
40. Gross HA, Ebert MH, Faden VB, Goldberg SC, et al. (1981). A double-blind controlled trial of lithium carbonate primary anorexia nervosa. Journal of Clinical Psychopharmacology 1, 376-381. (Pubitemid 12189861)
41. Gundlah C, Alves SE, Clark JA, Pai LY, et al. (2005). Estrogen receptor-beta regulates tryptophan hydroxylase- 1 expression in the murine midbrain raphe. Biological Psychiatry 57, 938-942. (Pubitemid 40488365)
42. Halbreich U, Kahn LS (2001). Role of estrogen in the aetiology and treatment of mood disorders. CNS Drugs 15, 797-817. (Pubitemid 33065429)
43. Halmi KA, Eckert E, LaDu TJ, Cohen J (1986). Anorexia nervosa. Treatment efficacy of cyproheptadine and amitriptyline. Archives of General Psychiatry 43, 177-181. (Pubitemid 16163536)
44. Howland RH, Wilson MG, Kornstein SG, Clayton AH, et al. (2008). Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression. Annals of Clinical Psychiatry 20, 209-218.
45. Hu XZ, Rush AJ, Charney D, Wilson AF, et al. (2007). Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Archives of General Psychiatry 64, 783-792. (Pubitemid 47026374)
46. Hudson JI, Hiripi E, Pope HG, Kessler RC (2007). The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biological Psychiatry 61, 348-358. (Pubitemid 46108682)
47. Jabbi M, Korf J, Kema IP, Hartman C, et al. (2007). Convergent genetic modulation of the endocrine stress response involves polymorphic variations of 5-HTT, COMT and MAOA. Molecular Psychiatry 12, 483-490. (Pubitemid 46652463)
48. Jarva JA, Oinonen KA (2007). Do oral contraceptives act as mood stabilizers? Evidence of positive affect stabilization. Archives of Womens Mental Health 10, 225-234. (Pubitemid 47493628)
49. Jimerson DC, Lesem MD, Kaye WH, Hegg AP, et al. (1990). Eating disorders and depression: is there a serotonin connection? Biological Psychiatry 28, 443-454. (Pubitemid 20245642)
50. Jovanovic H, Lundberg J, Karlsson P, Cerin A, et al. (2008). Sex differences in the serotonin 1A receptor and serotonin transporter binding in the human brain measured by PET. Neuroimage 39, 1408-1419.
51. Kaye W, Gendall K, Strober M (1998). Serotonin neuronal function and selective serotonin reuptake inhibitor treatment in anorexia and bulimia nervosa. Biological Psychiatry 44, 825-838. (Pubitemid 28520221)
52. Kaye WH, Frank GK, Bailer UF, Henry SE (2005). Neurobiology of anorexia nervosa: clinical implications of alterations of the function of serotonin and other neuronal systems. International Journal of Eating Disorders 37 (Suppl.) S15-S19; discussion S20-S11. (Pubitemid 40605015)
53. Kaye WH, Fudge JL, Paulus M (2009). New insights into symptoms and neurocircuit function of anorexia nervosa. Nature Reviews Neuroscience 10, 573-584.
54. Kaye WH, Gwirtsman HE, George DT, Ebert MH (1991). Altered serotonin activity in anorexia nervosa after long-term weight restoration. Does elevated cerebrospinal fluid 5-hydroxyindoleacetic acid level correlate with rigid and obsessive behavior? Archives of General Psychiatry 48, 556-562.
55. Kaye WH, Gwirtsman HE, George DT, Ebert MH, et al. (1987). Elevated cerebrospinal fluid levels of immunoreactive corticotropin-releasing hormone in anorexia nervosa: relation to state of nutrition, adrenal function, and intensity of depression. Journal of Clinical Endocrinology & Metabolism 64, 203-208. (Pubitemid 17001047)
56. Keating C (2009). Theoretical perspective on anorexia nervosa: the conflict of reward. Neuroscience & Biobehavioral Reviews 34, 73-79.
57. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, et al. (2008). Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Medicine 5, e45.
58. Klaiber EL, Broverman DM, Vogel W, Kobayashi Y (1979). Estrogen therapy for severe persistent depressions in women. Archives of General Psychiatry 36, 550-554. (Pubitemid 9201186)
59. Kugaya A, Epperson CN, Zoghbi S, van Dyck CH, et al. (2003). Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in postmenopausal women. American Journal of Psychiatry 160, 1522-1524. (Pubitemid 41070932)
60. Kulkarni J, de Castella A, Fitzgerald PB, Gurvich CT, et al. (2008). Estrogen in severe mental illness : a potential new treatment approach. Archives of General Psychiatry 65, 955-960.
61. Landry M, Di Paolo T (2003). Effect of chronic estradiol, tamoxifen or raloxifene treatment on serotonin 5-HT1A receptor. Brain Research. Molecular Brain Research 112, 82-89. (Pubitemid 36369249)
62. Lesch KP, Heils A (2000). Serotonergic gene transcriptional control regions : targets for antidepressant drug development? International Journal of Neuropsychopharmacology 3, 67-79. (Pubitemid 30354455)
63. Licinio J, Wong ML, Gold PW (1996). The hypothalamicpituitary- adrenal axis in anorexia nervosa. Psychiatry Research 62, 75-83. (Pubitemid 26151791)
64. Lo Sauro C, Ravaldi C, Cabras PL, Faravelli C, et al. (2008). Stress, hypothalamic-pituitary-adrenal axis and eating disorders. Neuropsychobiology 57, 95-115.
65. Lu NZ, Shlaes TA, Gundlah C, Dziennis SE, et al. (1999). Ovarian steroid action on tryptophan hydroxylase protein and serotonin compared to localization of ovarian steroid receptors in midbrain of guinea pigs. Endocrine 11, 257-267. (Pubitemid 30163335)
66. Maron E, Tammiste A, Kallassalu K, Eller T, et al. (2009). Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. European Journal of Neuropsychopharmacology 19, 451-456.
67. Matsushita S, Suzuki K, Murayama M, Nishiguchi N, et al. (2004). Serotonin transporter regulatory region polymorphism is associated with anorexia nervosa. American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics 128B, 114-117. (Pubitemid 38849929)
68. McEwen BS (2001). Invited review: Estrogens effects on the brain : multiple sites and molecular mechanisms. Journal of Applied Physiology 91, 2785-2801. (Pubitemid 33108046)
69. Meyer JH, Ginovart N, Boovariwala A, Sagrati S, et al. (2006). Elevated monoamine oxidase a levels in the brain : an explanation for the monoamine imbalance of major depression. Archives of General Psychiatry 63, 1209-1216. (Pubitemid 44708079)
70. Miller JM, Brennan KG, Ogden TR, Oquendo MA, et al. (2009). Elevated serotonin 1A binding in remitted major depressive disorder : evidence for a trait biological abnormality. Neuropsychopharmacology 34, 2275-2284.
71. Miller JM, Oquendo MA, Ogden RT, Mann JJ, et al. (2008). Serotonin transporter binding as a possible predictor of one-year remission in major depressive disorder. Journal of Psychiatric Research 42, 1137-1144.
72. Misra M, Miller KK, Almazan C, Ramaswamy K, et al. (2004). Alterations in cortisol secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism. Journal of Clinical Endocrinology & Metabolism 89, 4972-4980. (Pubitemid 39391436)
73. Monteleone P, Luisi M, Colurcio B, Casarosa E, et al. (2001). Plasma levels of neuroactive steroids are increased in untreated women with anorexia nervosa or bulimia nervosa. Psychosomatic Medicine 63, 62-68. (Pubitemid 32125358)
74. Morishita S, Kinoshita T (2008). Predictors of response to sertraline in patients with major depression. Human Psychopharmacology 23, 647-651.
75. Nemeroff CB, Vale WW (2005). The neurobiology of depression: inroads to treatment and new drug discovery. Journal of Clinical Psychiatry 66 (Suppl. 7), 5-13. (Pubitemid 41345489)
76. Ohara K, Nagai M, Suzuki Y, Ohara K (1998). Low activity allele of catechol-O-methyltransferase gene and Japanese unipolar depression. NeuroReport 9, 1305-1308. (Pubitemid 28264240)
77. Oinonen KA, Mazmanian D (2002). To what extent do oral contraceptives influence mood and affect? Journal of Affective Disorders 70, 229-240. (Pubitemid 34786641)
78. Ostlund H, Keller E, Hurd YL (2003). Estrogen receptor gene expression in relation to neuropsychiatric disorders. Annals of the New York Academy of Sciences 1007, 54-63. (Pubitemid 38258338)
79. Ott MA, Sayegh MA, Shew ML, Fortenberry JD (2005). Oral contraceptives influence mood and affect? Journal of Adolescent Health 36, 144.
80. Pae CU, Mandelli L, Kim TS, Han C, et al. (2009). Effectiveness of antidepressant treatments in premenopausal vs. post-menopausal women: a pilot study on differential effects of sex hormones on antidepressant effects. Biomedicine & Pharmacotherapy 63, 228-235.
81. Pariante CM, Lightman SL (2008). The HPA axis in major depression: classical theories and new developments. Trends in Neuroscience 31, 464-468.
82. Parker KJ, Schatzberg AF, Lyons DM (2003). Neuroendocrine aspects of hypercortisolism in major depression. Hormones and Behavior 43, 60-66. (Pubitemid 36293275)
83. Parsey RV, Olvet DM, Oquendo MA, Huang YY, et al. (2006). Higher 5-HT1A receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study. Neuropsychopharmacology 31, 1745-1749. (Pubitemid 44106705)
84. Pecins-Thompson M, Brown NA, Kohama SG, Bethea CL (1996). Ovarian steroid regulation of tryptophan hydroxylase mRNA expression in rhesus macaques. Journal of Neuroscience 16, 7021-7029. (Pubitemid 26359381)
85. Raz L, Khan MM, Mahesh VB, Vadlamudi RK, et al. (2008). Rapid estrogen signaling in the brain. Neurosignals 16, 140-153. (Pubitemid 351263221)
86. Rocha BA, Fleischer R, Schaeffer JM, Rohrer SP, et al. (2005). 17 Beta-estradiol-induced antidepressant-like effect in the forced swim test is absent in estrogen receptor-beta knockout (BERKO) mice. Psychopharmacology (Berlin) 179, 637-643. (Pubitemid 40674765)
87. Rossi G, Balottin U, Rossi M, Chiappedi M, et al. (2007). Pharmacological treatment of anorexia nervosa: a retrospective study in preadolescents and adolescents. Clinical Pediatrics (Philadelphia) 46, 806-811. (Pubitemid 47556552)
88. Sargent PA, Kjaer KH, Bench CJ, Rabiner EA, et al. (2000). Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Archives of General Psychiatry 57, 174-180. (Pubitemid 30075269)
89. Schmidt PJ, Nieman L, Danaceau MA, Tobin MB, et al. (2000). Estrogen replacement in perimenopause-related depression: a preliminary report. American Journal of Obstetrics & Gynecology 183, 414-420. (Pubitemid 30651090)
90. Schule C (2007). Neuroendocrinological mechanisms of actions of antidepressant drugs. Journal of Neuroendocrinology 19, 213-226. (Pubitemid 46210949)
91. Seed JA, McCue PM, Wesnes KA, Dahabra S, et al. (2002). Basal activity of the HPA axis and cognitive function in anorexia nervosa. International Journal of Neuropsychopharmacology 5, 17-25. (Pubitemid 34241063)
92. Smits KM, Smits LJ, Peeters FP, Schouten JS, et al. (2008). The influence of 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene on treatment effect of selective serotonin reuptake inhibitors in depressive patients. Psychiatric Genetics 18, 184-190.
93. Soares CN, Almeida OP, Joffe H, Cohen LS (2001). Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Archives of General Psychiatry 58, 529-534. (Pubitemid 32523731)
94. Soares CN, Zitek B (2008). Reproductive hormone sensitivity and risk for depression across the female life cycle : a continuum of vulnerability? Journal of Psychiatry & Neuroscience 33, 331-343. (Pubitemid 351977159)
95. Sodersten P, Bergh C (2008). Serotonin transporter binding in eating disorders. Psychopharmacology (Berlin) 197, 519-520; author reply 521-512.
96. Sodersten P, Nergardh R, Bergh C, Zandian M, et al. (2008). Behavioral neuroendocrinology and treatment of anorexia nervosa. Frontiers in Neuroendocrinology 29, 445-462.
97. Solomon MB, Herman JP (2009). Sex differences in psychopathology : of gonads, adrenals and mental illness. Physiology & Behavior 97, 250-258.
98. Sullivan PF (1995). Mortality in anorexia nervosa. American Journal of Psychiatry 152, 1073-1074.
99. Sullivan GM, Oquendo MA, Huang YY, Mann JJ (2006). Elevated cerebrospinal fluid 5-hydroxyindoleacetic acid levels in women with comorbid depression and panic disorder. International Journal of Neuropsychopharmacology 9, 547-556. (Pubitemid 44607207)
100. Sysko R, Sha N, Wang Y, Duan N, et al. (2010). Early response to antidepressant treatment in bulimia nervosa. Psychological Medicine 40, 999-1005.
101. Taber KH, Murphy DD, Blurton-Jones MM, Hurley RA (2001). An update on estrogen: higher cognitive function, receptor mapping, neurotrophic effects. Journal of Neuropsychiatry & Clinical Neurosciences 13, 313-317. (Pubitemid 32743708)
102. Thomson F, Craighead M (2008). Innovative approaches for the treatment of depression: targeting the HPA axis. Neurochemical Research 33, 691-707. (Pubitemid 351341638)
103. Tilbrook AJ, Clarke IJ (2006). Neuroendocrine mechanisms of innate states of attenuated responsiveness of the hypothalamo-pituitary adrenal axis to stress. Frontiers in Neuroendocrinology 27, 285-307. (Pubitemid 44550215)
104. Tsai MH, Lin KM, Hsiao MC, Shen WW, et al. (2010). Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopramand treatment response. Pharmacogenomics 11, 537-546.
105. Ur E, Dinan TG, OKeane V, Clare AW, et al. (1992). Effect of metyrapone on the pituitary-adrenal axis in depression: relation to dexamethasone suppressor status. Neuroendocrinology 56, 533-538.
106. Veenstra-VanderWeele J, Anderson GM, Cook EH (2000). Pharmacogenetics and the serotonin system: initial studies and future directions. European Journal of Pharmacology 410, 165-181. (Pubitemid 32008142)
107. von Bardeleben U, Stalla GK, Muller OA, Holsboer F (1988). Blunting of ACTH response to human CRH in depressed patients is avoided by metyrapone pretreatment. Biological Psychiatry 24, 782-786.
108. Wade TD, Bulik CM, Neale M, Kendler KS (2000). Anorexia nervosa and major depression: shared genetic and environmental risk factors. American Journal of Psychiatry 157, 469-471. (Pubitemid 30145940)
109. Walsh BT, Kaplan AS, Attia E, Olmsted M, Parides M, et al. (2006). Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial. Journal of the American Medical Association 295, 2605-2612. (Pubitemid 43882335)
110. Walsh BT, Katz JL, Levin J, Kream J, et al. (1981). The production rate of cortisol declines during recovery from anorexia nervosa. Journal of Clinical Endocrinology & Metabolism 53, 203-205. (Pubitemid 13245405)
111. Weinstock M, Razin M, Schorer-Apelbaum D, Men D, et al. (1998). Gender differences in sympathoadrenalactivity in rats at rest and in response to footshock stress. International Journal of Developmental Neuroscience 16, 289-295. (Pubitemid 28427094)
112. Westlund Tam L, Parry BL (2003). Does estrogen enhance the antidepressant effects of fluoxetine? Journal of Affective Disorders 77, 87-92. (Pubitemid 37205155)
113. Wust S, Kumsta R, Treutlein J, Frank J, et al. (2009). Sexspecific association between the 5-HTT gene-linked polymorphic region and basal cortisol secretion. Psychoneuroendocrinology 34, 972-982.
114. Yokoyama S, Sugiyama N, Sugiyama E, Amano N (2008). Five female cases of prolonged depression in chronic anorexia nervosa treated with selective estrogen receptor modulator raloxifene-augmented therapy. Journal of Clinical Psychopharmacology 28, 721-722.
115. Young EA, Akil H, Haskett RF, Watson SJ (1995). Evidence against changes in corticotroph CRF receptors in depressed patients. Biological Psychiatry 37, 355-363.
116. Young EA, Altemus M, Parkison V, Shastry S (2001). Effects of estrogen antagonists and agonists on the ACTH response to restraint stress in female rats. Neuropsychopharmacology 25, 881-891. (Pubitemid 34031893)
117. Young EA, Lopez JF, Murphy-Weinberg V, Watson SJ, et al. (1997). Normal pituitary response to metyrapone in the morning in depressed patients : implications for circadian regulation of corticotropin-releasing hormone secretion. Biological Psychiatry 41, 1149-1155. (Pubitemid 27237175)
118. Zanardi R, Rossini D, Magri L, Malaguti A, et al. (2007). Response to SSRIs and role of the hormonal therapy in post-menopausal depression. European Neuropsychopharmacology 17, 400-405. (Pubitemid 46497659)
119. Zobel AW, Nickel T, Kunzel HE, Ackl N, et al. (2000). Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. Journal of Psychiatric Research 34, 171-181. (Pubitemid 30364916)